(Q34650664)

English

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

scientific article

Statements

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial (English)
Piotr Tomczak
Thomas E Hutson
M Dror Michaelson
Sylvie Negrier
Stephane Oudard
Martin E Gore
Jamal Tarazi
Subramanian Hariharan
Connie Chen
Brad Rosbrook
Brian I Rini

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit